Selective targeting of single Th17 cytokines, such as IL-17 or GM-CSF, with monoclonal antibodies has not shown efficacy in MS and in other autoimmune diseases such as Crohn's disease and rheumatoid arthritis, although the involvement of Th17 cells in their pathogenesis has been widely documented. This evidence concerns the gene IL17A and rheumatoid arthritis.